Navigation Links
Hanger, Inc. Reports Earnings of $0.50 Per Diluted Share for the Second Quarter 2012
Date:8/1/2012

AUSTIN, Texas, Aug. 1, 2012 /PRNewswire/ -- Hanger, Inc. (NYSE: HGR) announced net sales of $251.8 million for the quarter ended June 30, 2012, an increase of $17.0 million, or 7.2%, from $234.8 million for the second quarter of 2011.
Diluted earnings per share increased 11.1% to $0.50 for the second quarter of 2012 compared to diluted earnings per share of $0.45 in the same period in 2011. 

The increase in net sales of $17.0 million, or 7.2%, for the second quarter of 2012 was the result of an $8.8 million, or 4.6%, increase in same-center sales in the patient-care services segment; a $5.9 million increase from acquired entities; a $1.8 million, or 7.2%, increase in sales in the distribution segment; and a $0.3 million increase from the therapeutic solutions segment.  The increase in revenues, together with continued expense control, resulted in an 8.6%, or $2.8 million, increase in income from operations to $35.7 million for the three months ended June 30, 2012 compared to income from operations of $32.9 million for the same period in 2011.Net sales for the six months ended June 30, 2012 increased $34.6 million, or 8.0%, to $469.8 million from $435.2 million in 2011.  The sales increase was driven by a $20.1 million, or 5.7%, increase in same-center sales in the patient-care services segment; a $10.5 million increase from acquired entities; a $4.6 million, or 9.4%, increase in sales in the distribution segment; and a $0.6 million decrease from the therapeutic solutions segment.  The increase in sales resulted in a 14.3%, or $0.09 per diluted share, increase in diluted earnings per share to $0.72 for the six months ended June 30, 2012 from $0.63 in the same period in 2011.

The Company's cash flow from operations increased $16.4 million to $27.0 million during the six months ended June 30, 2012 compared to $10.6 million in 2011.
Through July 2012, the Company acquired seven patient care companies comprised of thirteen clinics with annualized revenue of $12.8 million.  As of June 30, 2012, the Company had $141.1 million in total liquidity, which included $41.6 million of cash and $99.5 million available under its revolving credit facility, net of $0.5 million in letters of credit.  The Company's leverage ratio, as defined in its credit facilities, improved to 2.9 at June 30, 2012 from 3.0 at December 31, 2011.

"We continue to deliver strong revenue growth in our patient-care services and our distribution segments.  This, combined with solid operational execution demonstrated by our talented employees around the country, has resulted in 11.1% growth in diluted earnings per share," commented Vinit K. Asar, Chief Executive Officer of Hanger.  "Our operations continue to generate good cash flow as we execute our planned investments in programs, acquisitions, and infrastructure improvements that will continue to provide a sustainable platform for future growth."

The Company expects full year 2012 revenues between $970 million and $990 million resulting from a comparable store sales growth in our patient-care services segment of 3% to 5% and growth in our distribution segment of 3% to 5%. We expect flat to slightly higher revenues in our therapeutic services segment for the year, with sales in the first half of the year down then trending up the second half as the rate of new contract sales accelerates. The Company has raised the lower end of its earnings guidance range and now anticipates diluted earnings per share between $1.75 and $1.79, excluding approximately $0.01 per diluted share in one-time training costs related to the implementation of Janus, the Company's new practice management and billing system. As in past years, the Company's goal is to increase operating margins by twenty to forty basis points. The Company anticipates generating cash flow from operations between $70 million and $80 million in 2012 and investing a total of $40 million to $50 million in capital additions.  The Company will continue its acquisition program with a goal of closing acquisitions that total approximately $20 million in annualized revenues.

A conference call to discuss these results is scheduled to begin at 9:00 a.m., EDT, on Thursday, August 2, 2012. Those wishing to participate should call 1-877-312-5846. In addition, a replay will be available until Friday, August 10, 2012, by dialing 1-855-859-2056 and referencing Conference ID # 88640671.

About Hanger - Hanger, Inc., headquartered in Austin, Texas, is the world's premier provider for services and products that enhance human physical capability.  Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger is steeped in 150 years of clinical excellence and innovation.  Hanger provides orthotic and prosthetic patient care services, distributes O&P devices and components,  and provides therapeutic solutions to the broader post-acute market.  Hanger is the largest owner and operator of orthotic and prosthetic patient care clinics with in excess of 700 O&P patient care clinics located in 45 states and the District of Columbia.  Hanger, through its subsidiary Southern Prosthetic Supply, Inc, is also the largest distributor of branded and private label O&P devices and components in the United States.  Hanger provides therapeutic solutions through its subsidiaries Innovative Neurotronics and Accelerated Care Plus.  Innovative Neurotronics introduces emerging neuromuscular technologies developed through independent research in a collaborative effort with industry suppliers worldwide.  Accelerated Care Plus is a developer of specialized rehabilitation technologies and the nation's leading provider of evidence-based clinical programs for post-acute rehabilitation serving more than 4,000 long-term care facilities and other sub-acute rehabilitation providers throughout the U.S.  For more information on Hanger, visit www.hanger.com and follow us at www.Facebook.com/HangerNews, www.Twitter.com/HangerNews, and www.YouTube.com/HangerNews

This document contains forward-looking statements relating to the Company's results of operations.  The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.  Statements relating to future results of operations in this document reflect the current views of management.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products and the other factors identified in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.  The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 Hanger , Inc.(in thousands, except for share and per share amounts)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,Income Statement:2012201120122011Net sales

$
251,754$
234,751$
469,846$
435,190Cost of goods sold - materials

72,89968,514136,998126,622Personnel costs

83,43581,014167,054159,903Other operating expenses

51,25644,60393,38981,993Relocation expenses

-42-417Depreciation and amortization

8,4387,69616,72314,988Income from operations

35,72632,88255,68251,267Interest expense

7,6847,79115,46116,170Income before taxes

28,04225,09140,22135,097Provision for income taxes

10,6569,66015,28013,453Net income

$
7,386$
5,431$
24,941$
21,644Basic Per Common  Share Data:Net income

$
.51$
.46$
.73$
.65Shares used to compute basic per share amounts

34,268,94133,499,26834,110,82033,429,502Diluted Per Common Share Data:Net income 

$
.50$
.45$
.72$
.63Shares used to compute diluted per share amounts

34,720,48934,365,39534,637,76934,284,513Reconciliation of GAAP financial measures to Non-GAAP financial measuresIncome from Operations

$
35,726$
32,882$
55,682$
51,267Relocation expenses

-42-417Adjusted Income from Operations

$
35,726$
32,924$
55,682$
51,684Net income 

$
7,386$
5,431$
24,941$
21,644Relocation expenses

-42-417Tax effect of adjustments

-(16)-(161)Adjusted net income 

$
7,386$
5,457$
24,941$
21,900Adjusted net income per diluted share

$
.50$
.45$
.72$
.64Three Months EndedSix Months EndedJune 30, June 30, Income Statement as a % of Net Sales:2012201120122011Net sales

100.0%100.0%100.0%100.0%Cost of goods sold - materials

29.0%29.2%29.2%29.1%Personnel costs

33.1%34.5%35.5%36.7%Other operating expenses

20.3%19.0%19.9%18.8%Relocation expenses

0.0%0.0%0.0%0.1%Depreciation and amortization

3.4%3.3%3.5%3.4%Income from operations

14.2%14.0%11.9%11.9%Interest expense

3.1%3.3%3.3%3.7%Income before taxes

11.1%10.7%8.6%8.2%Provision for income taxes

4.2%4.1%3.3%3.1%Net income 

6.9%6.6%5.3%5.1%Adjusted income from operations

14.2%14.0%11.9%11.9%Adjusted net income

6.9%6.6%5.3%5.0%Hanger , Inc.(in thousands, except for statistical data)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30, Cash Flow Data:2012201120122011Cash flow provided by operations 

$
25,709$
22,328$
27,001$
,638Capital expenditures

$
,654$
9,210$
5,970$
5,269Increase/(decrease) in cash and cash equivalents

$
9,365$
(140)$
(1,283)$
(16,782)Balance Sheet Data:June 30, 2012December 31, 2011Cash and cash equivalents$
41,613$
42,896Days Sales Outstanding (DSO's)5454Working Capital $
265,854$
241,729Total Debt$
504,427$
508,033Shareholders' Equity$
460,418$
429,663Three Months EndedSix Months EndedJune 30,June 30,2012201120122011Revenue Mix:Patient-care services

82.6%82.2%81.9%81.3%Distribution

10.9%10.9%11.4%11.3%Therapeutic solutions

6.5%6.9%6.7%7.4%Patient Care Payor Mix:Commercial and other

58.6%59.2%58.7%59.4%Medicare

29.5%28.5%29.4%28.4%Medicaid

5.9%6.9%5.9%6.8%VA

6.0%5.4%6.0%5.4% 

Management relies on the non-GAAP items as the primary measures to review and assess operating performance and management teams. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  Management and investors also review the non-GAAP items to evaluate the Company's overall performance and to compare its current operating results with corresponding periods and with other companies in the health care industry. You should not consider the non-GAAP items in isolation or as a substitute for net income, operating cash flows or other cash flow statement data determined in accordance with accounting principles generally accepted in the United States. Because the non-GAAP items are not measures of financial performance under accounting principles generally accepted in the United States and are susceptible to varying calculations, they may not be comparable to similarly titled measures of other companies.  Adjusted net income, Adjusted income from operations, and Adjusted net income per diluted share are the non-GAAP financial measures.


'/>"/>
SOURCE Hanger, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hanger Orthopedic Group, Inc. announces name change to Hanger, Inc.
2. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, ... St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was ... address the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered ...
(Date:5/5/2016)... ... , ... Is the part in your hair widening? Are you finding more ... a good opportunity to raise awareness about a common condition among women: hair loss. ... women experience hair loss or ‘thinning’ by the time they reach menopause, but many ...
(Date:5/4/2016)... ... 04, 2016 , ... ProList is a set of 30 self-animating bullet points ... editors can easily create lists for presentations, youtube productions, and more. Simply choose ... is the perfect complement to presentation style videos. , ProList is a package of ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... and interview techniques, seeks to add a deeper understanding of the program, policy ... weaknesses, and each answers different yet important questions. , In a new brief ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Business Conference. The conference opened on Tuesday with Frank Luntz, sharing a dynamic, ... PDMP Solution provided a deep dive on NCPDP’s model solution to help stem ...
Breaking Medicine News(10 mins):